Drug intelligence / Profile preview

miltuximab

Development stage: Unknown
Lead developer: GlyTherix
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Miltuximab is a chimeric monoclonal antibody targeting **Glypican-1 (GPC-1)**, a cell surface proteoglycan that is highly expressed in several solid tumors, notably prostate cancer. It is being developed as a **theranostic** agent, combining diagnostic imaging (radioimmunoconjugates) and potential therapeutic applications. Early clinical studies show promising safety and tumor-targeting capabilities. The agent has been evaluated in metastatic cancers such as prostate, pancreatic, and bladder cancer, and radiolabeled forms (e.g., [^67Ga]Ga-DOTA-Miltuximab®) are being studied for imaging and therapy in prostate cancer patients who have failed prior treatments[2][4][6].

Brand names: MiltuximabMiltuximab®
Other names: Miltuximab

Targets

GPC1 (Glypican-1)

Beyond the preview

Go deeper on miltuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miltuximab.

Explore the full profile